More recent published data also revealed the effect of bexarotene on an intensive reduction in Aβ plaques and improvement of cognitive function in three genetically modified mouse models of AD (APPswe/PSEN1dE9—at a dose of 100 mg/kg for 3, 7, 14 or 90 days; APP/PS1-21—at a dose of 100 mg/kg for 20 days; and Tg2576—at a dose of 100 mg/kg for 3 or 7 days). Here, APP is linked to Alzheimer disease.